Skip to content

Orforglipron

Also called LY3502970 (oral non-peptide GLP-1)

First oral small-molecule (non-peptide) GLP-1 agonist.

  • TypeSmall molecule
  • FormOral
  • Researched forMetabolic & Fat Loss

Where to get Orforglipron

Flawless Compounds
Oral
Code CAMERON

21+ to enter. Sold as the form named. Approved uses are on its label; the research here goes beyond them.

Shop oral at Flawless Compounds

The short version

  • Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
  • What the evidence isFDA-approved on 1 April 2026 as Foundayo, for long-term weight management in adults with obesity, or overweight with at least one weight-related condition (Lilly, 1 Apr 2026).
  • What to watchSevere belly pain with vomiting.

How Orforglipron works

First oral small-molecule (non-peptide) GLP-1 agonist — cAMP-biased partial agonist; food-independent absorption, no injection.

Every other GLP-1 drug in this catalog is a peptide. This one is not, and that single fact generates everything else on the page.

It is a partial agonist, and it is biased. The same work reports partial agonism at the GLP-1 receptor with signaling biased toward G protein activation over beta-arrestin recruitment Kawai 2020. Beta-arrestin is the arm that internalizes and desensitizes a receptor after it fires.

  • Oral

On the goal map: Appetite & satiety signaling (Lose fat)

Research on Orforglipron5 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: FDA-approved for obesity (Foundayo, Apr 2026).

Human clinical evidence

  • FDA-approved on 1 April 2026 as Foundayo, for long-term weight management in adults with obesity, or overweight with at least one weight-related condition (Lilly, 1 Apr 2026). Eli Lilly's oral, non-peptide GLP-1 agonist. The ACHIEVE and ATTAIN programs reported HbA1c reduction in type 2 diabetes and weight loss in the 11–12% range at 72 weeks in obesity.

  • Read the number in context: it is below injectable semaglutide and well below tirzepatide, and above oral semaglutide. The trade is convenience against magnitude, not a new efficacy ceiling.

Correlative data

  • Marketed in the US only since April 2026, so real-world use is months old. Consistent with the class.

How the mechanism reads

  • A small molecule, not a peptide — which is the whole story. Peptides are destroyed by digestion, which is why oral semaglutide needs an absorption enhancer and still achieves roughly 1% bioavailability with strict fasting requirements.

    Mechanistic
  • A non-peptide agonist sidesteps all of that: no injection, no absorption enhancer, no food-timing restrictions, and manufacturing at chemical rather than biological cost. That last point is why this molecule matters for access even though its effect size is not class-leading.

    Mechanistic

Sources

  • Kawai T, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proceedings of the National Academy of Sciences 2020 · PMID 33177239
  • Morse BL, et al. Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clinical Pharmacology in Drug Development 2025 · PMID 40888509
  • Ma X, et al. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Therapy 2024 · PMID 38402332
  • Horn DB, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. The Lancet 2025 · PMID 41275875
  • Wharton S, et al. Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials. Diabetes, Obesity and Metabolism 2026 · PMID 42338042
  • Shirley M. Orforglipron: First Approval. Drugs 2026 · PMID 42479349

Orforglipron safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Personal or family history of medullary thyroid cancer or MEN2: a GLP-1 receptor class warning.
  • History of pancreatitis or severe gastroparesis: slowed gastric emptying and pancreatic stimulation.
  • Type 1 diabetes or insulin or sulfonylurea use: glucose can drop further.
  • Strong CYP3A4 inducers or inhibitors: the drug is cleared through CYP3A4, so levels shift.
  • Pregnancy or trying to conceive: deliberate weight loss is not advised in pregnancy, and no human pregnancy data exist.

What’s expected

  • Lower appetite and early fullness, via GLP-1 receptor cAMP signaling.
  • Nausea, constipation or loose stools early on.
  • Slight rise in resting pulse.
  • No needle required, and absorption that does not depend on food.

Watch for

  • Severe belly pain with vomiting.
  • Right upper pain or yellow eyes.
  • Vision change if you have diabetes.
  • Little urine, dizziness and dry mouth from dehydration.

Labs that tell you it’s working

  • HbA1c (Hemoglobin A1c)
  • Lipase
  • Comprehensive Metabolic Panel (CMP)
  • Cystatin C with eGFR

Orforglipron is an oral, non-peptide, cAMP-biased GLP-1 agonist cleared via CYP3A4; GLP-1 class effects apply without a glucagon arm. PMID 41275875 PMID 42338042

Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON

A panel picked from how it works and what it can move: the tests, and why each is on it.

9 tests in one order
Marek Diagnostics · no doctor’s visit
Code CAMERON
Order this panel

Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.

The “On a GLP-1 (Semaglutide / Tirzepatide)” panel, explained

Orforglipron FAQ4 common questions

Is Orforglipron approved for human use?
Orforglipron is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
What is Orforglipron researched for?
Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Which labs show whether it's doing anything?
HbA1c; Lipase; Comprehensive Metabolic Panel; Cystatin C with eGFR: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Orforglipron: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Orforglipron is. Skool covers how it is run.

Free on this page

What Orforglipron is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Orforglipron is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool